Okyo Pharma Reports Encouraging Corneal Nerve Improvements in Phase 2 Study for Neuropathic Corneal Pain
Okyo Pharma (NASDAQ: OKYO) released new Phase 2 data showing that its lead candidate OK-101 produced favorable corneal nerve changes in patients with neuropathic corneal pain (NCP), a chronic and difficult-to-treat condition with limited therapeutic options.
Using in vivo confocal microscopy, investigators observed improvements in corneal nerve fiber length, density, and branching compared with baseline. These objective biological markers reinforce earlier findings of reduced pain severity and support the idea that OK-101 may influence the underlying nerve dysfunction driving NCP.
The treatment continued to demonstrate a clean safety profile, adding confidence as the company prepares for late-stage development.
From an investor perspective, these results are notable because they strengthen the mechanistic rationale for OK-101 and provide measurable evidence beyond patient-reported pain scores. Objective nerve regeneration signals are uncommon in ophthalmic pain studies and may help differentiate OK-101 from symptomatic treatments.
Bottom Line
The new Phase 2 nerve-health data deepen Okyo Pharma’s evidence base for OK-101 and support advancement toward a pivotal trial. If confirmed in larger studies, OK-101 could become a first-in-class treatment in a niche but underserved ophthalmic pain market.
